Highlights

  • Pro Medicus (ASX:PME) shares were trading at A$169.36, down 0.14% at the time of writing on 9 September 2026.
  • Australian healthcare stocks were broadly weaker, with the S&P/ASX 200 Health Care index down 1.69%.
  • Pro Medicus reported FY26 Revenue of A$261.7 million and underlying NPAT of A$144.7 million.
  • The company signed 10 new contracts worth at least A$407 million during FY26 and remained debt-free.

Pro Medicus Limited (ASX:PME) shares were little changed on Wednesday, with the stock trading at A$169.36, down 0.14% at the time of writing on 9 September 2026.

The move came during a softer session for Australian equities. The S&P/ASX 200 (ASX:XJO) was trading at 8,896.00 points, down 0.28% at the time of writing on 9 September 2026, while the S&P/ASX 300 (ASX:XKO) stood at 8,824.90 points, down 0.31%.

Healthcare stocks faced heavier pressure, with the S&P/ASX 200 Health Care (ASX:XHJ) trading at 31,299.70 points, down 1.69% at the time of writing on 9 September 2026.

Pro Medicus therefore outperformed the healthcare benchmark on the day despite finishing slightly lower. With no specific catalyst supplied for Wednesday’s share-price movement, the decline should not be attributed to any particular corporate event. A small daily move can reflect trading flows, portfolio adjustments or broader market sentiment without signalling a material change in Business fundamentals.

Medical Imaging Platform

Pro Medicus is a healthcare informatics company providing medical imaging software and services to hospitals, imaging centres and healthcare groups globally.

Its flagship Visage 7 platform supports radiology imaging workflows and is designed to provide high-speed access to medical images in both public and private cloud environments. The company’s offering spans picture archiving and communication systems, radiology information systems, artificial intelligence and other digital healthcare solutions.

Pro Medicus has offices in Melbourne, Berlin and San Diego, while North America has developed into a particularly important market for its growth strategy. The company’s model is increasingly tied to large-scale healthcare organisations seeking cloud-based imaging infrastructure that can manage substantial and growing volumes of diagnostic data.

For investors, the attraction of this model lies in scalability. Large healthcare contracts can generate Recurring Revenue over multi-year periods, although execution, customer implementations, renewals and competition remain important factors to monitor.

FY26 Growth

Pro Medicus released its FY26 full-year results on 18 August 2026, providing the most substantial recent operational update for investors.

The company reported revenue of A$261.7 million, up 22.9%, while underlying EBIT increased 24.4% to A$196.1 million. Underlying net profit after tax rose 24.1% to A$144.7 million.

Reported NPAT reached A$265.3 million, although the underlying figure may provide a clearer view of ongoing operating performance. Pro Medicus finished the year with A$252.3 million in cash and other financial assets, an increase of 19.7%, and remained debt-free.

On a constant-currency basis, underlying revenue reached A$273.5 million, up 28.4%, while underlying EBIT rose 30.6% to A$206.0 million. Underlying NPAT on the same basis increased 32.5% to A$154.5 million.

The company’s EBIT Margin expanded to 74.9%, up 90 basis points, reinforcing the high-margin characteristics of its software-led business model.

Contracts and Expansion

Contract momentum remained an important feature of FY26.

Pro Medicus signed 10 new contracts worth a minimum A$407 million during the year. It also renewed all six contracts that came up for renewal, with those agreements carrying a combined value of A$141 million over five-year terms.

Among the larger contracts was a 10-year A$170 million agreement with UCHealth Colorado, covering full-stack and cardiology solutions, alongside a seven-year A$90 million agreement with Beth Israel Lahey Health.

The company also continued to expand beyond its traditional radiology offering. FY26 included launches in digital pathology and AI-optimised reporting, broadening the potential application of its imaging technology.

Another area investors may watch is implementation progress. Pro Medicus said its major Trinity implementation was largely complete and positioned to make a full-year contribution in FY27.

This matters because signing a large contract and converting it into recognised revenue are separate stages. Implementation timing, customer deployment schedules and utilisation can influence how quickly contracted opportunities translate into reported financial performance.

What Investors Are Watching

Pro Medicus enters FY27 with several factors likely to shape investor expectations.

One is the continued penetration of Visage 7 across large US healthcare systems. North America has become a major growth engine for the company, and further contract wins or renewals could reinforce its competitive position in enterprise medical imaging.

Another is margin sustainability. An EBIT margin approaching three-quarters of revenue demonstrates considerable operating leverage, but investors may assess whether the company can sustain high profitability while investing in new products, implementation resources and broader market opportunities.

Innovation is equally important. The move into digital pathology, cardiology and AI-assisted reporting could expand the addressable market beyond conventional radiology workflows. At the same time, new product categories require successful commercial adoption to translate technological capability into meaningful revenue.

Valuation is another consideration. Companies with high margins, recurring revenue and rapid Earnings growth can command elevated market expectations. This can make their share prices sensitive not only to absolute results but also to whether growth meets, exceeds or falls short of investor assumptions.

For that reason, a small daily decline such as the current 0.14% move should be viewed in context rather than as a standalone judgement on the company’s fundamentals.

Final Takeaway

Pro Medicus (ASX:PME) shares were trading at A$169.36, down 0.14% at the time of writing on 9 September 2026, while the broader healthcare index was down 1.69%.

The modest share-price movement comes against a fundamentally important period for the medical imaging software company. Its August FY26 results showed revenue of A$261.7 million, underlying NPAT of A$144.7 million, 10 new contract wins worth at least A$407 million and a debt-free balance sheet.

Rather than reading too much into one trading session, investors are likely to focus on contract conversion, Trinity’s FY27 contribution, new customer wins, product expansion, margins and the continued adoption of Visage across major healthcare networks.